InvestorsHub Logo
Followers 6
Posts 533
Boards Moderated 0
Alias Born 04/16/2024

Re: None

Monday, 06/10/2024 7:01:53 PM

Monday, June 10, 2024 7:01:53 PM

Post# of 167
"[...] Emil D. Kakkis, MD, PhD, Chief Executive Officer and President of Ultragenyx. “By using an AAV8 variant validated in prior human and other studies combined with our scalable, efficient HeLa producer cell line platform, we believe we can leverage our mutual strengths to develop a high-quality AAV-based treatment alternative for Duchenne.”

https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-solid-biosciences-announce-strategic
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SLDB News